Frontlight ResearchEarly access
Chronic lymphocytic leukaemia trials in France
44 of 49 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Where
- Nantes
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT07221500 - Phase 3Taking peopleROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- Where
- Bordeaux, Clermont-Ferrand, Créteil, Le Mans Cedex 9, Lyon, Montpellier Cedex 5, Nice, Paris, Tours Cedex 9
- Age
- 18 years and over
- People
- 306 worldwide
- Run by
- Newave Pharmaceutical Inc
See details and how to joinNCT07342478 · EU 2026-525656-28-00 - Phase 1/2Taking peopleSafety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
- Where
- Paris, Poitiers, Rennes
- Age
- 1 year to 17 years
- People
- 70 worldwide
- Run by
- Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00 - Phase 1Taking peopleA Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
- Where
- Marseille, Pierre-Bénite, Toulouse, Tours
- People
- 225 worldwide
- Run by
- Janssen Cilag International
See details and how to join2026-525234-39-00 - Phase 3Taking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- Clermont-Ferrand, La Roche-sur-Yon, Lille
- Age
- 18 years and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - Phase 1WithdrawnA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Where
- Clermont-Ferrand, Toulouse
- Age
- 18 years and over
- People
- 332 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05091424 - Phase 2Taking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Argenteuil Cedex, Caen Cedex 9, Le Mans, Mulhouse, Nice Cedex 2, Tours Cedex 9
- Age
- 18 years and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - Phase 1Taking peopleA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Lille, Marseille, Nantes, Paris, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - Phase 4Not yet taking people in FranceA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Rouen
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - Phase 1/2Taking peopleA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Where
- Clermont-Ferrand, Montpellier Cedex 5, Paris, Saint-Cloud, Villejuif
- Age
- 18 years and over
- People
- 408 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00 - Phase 2Taking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Le Chesnay, Marseille, Nice, Paris, Pierre-Bénite
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - Phase 1/2Taking peopleA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Where
- Dijon, Montpellier Cedex 5, Toulouse Cedex 9
- Age
- 18 years and over
- People
- 258 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00 - Phase 3Taking peopleA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Where
- Clermont-Ferrand, Nantes, Paris Cedex 13, Pierre-Bénite, Reims Cedex, Rennes Cedex 9, Rouen, Toulouse Cedex 9, Vandoeuvre Les Nancy
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00 - Phase 3Not yet taking people in FranceSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Angers, La Roche-sur-Yon, Nantes, Rennes, Rouen
- Age
- 18 years and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - No phaseTaking peopleReassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax
- Where
- Amiens, Nantes
- Age
- 18 years and over
- People
- 130
- Run by
- Private Hospital of Confluent, France
See details and how to joinNCT07691047 - Phase 1/2Taking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Bordeaux, ClermontFerrand, Créteil, Lille, Lyon, Marseille, Montpellier, Paris, Rouen
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - Phase 3Taking peopleA phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
- Where
- Angers, Clermont-Ferrand, Grenoble Cedex 9, Lille Cedex, Lyon, Marseille, Montpellier Cedex 5, Nantes, Paris, Pessac Cedex, Pierre-Bénite, Poitiers, Reims Cedex, Rennes, Rouen Cedex, Toulouse Cedex 9, Tours Cedex 9, Vandoeuvre Les Nancy
- Age
- 18 years and over
- People
- 746 worldwide
- Run by
- University Of Cologne
See details and how to join2023-510294-34-00 - Phase 4Taking peopleRegistry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
- Where
- ANGERS Cedex 09, Grenoble Cedex 09, Nantes, Pessac, Rennes Cedex 9, Toulouse Cedex 9
- Age
- 18 years and over
- People
- 365 worldwide
- Run by
- Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 - Phase 3Not yet taking people in FranceA Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Where
- Brest, Nantes Cedex 2, Tours
- Age
- 18 years and over
- People
- 49 worldwide
- Run by
- Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00 - Phase 1/2Taking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Pessac, Villejuif
- Age
- 18 years and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - Phase 3Taking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Bordeaux, Clermont-Ferrand, Nantes, Paris, Rouen, Toulouse Cedex 9, Tours Cedex 9, Vandoeuvre Les Nancy Cedex
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - Phase 3Taking peopleA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- Where
- Bordeaux, Clermont-Ferrand, Le Mans Cedex 9, Lille Cedex, Lyon, Montpellier Cedex 5, Toulouse Cedex 9
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT07277231 · EU 2025-524366-21-00 - Phase 2Not yet taking people in FranceFILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
- Where
- Amiens Cedex 1, Argenteuil Cedex, Avignon, Bayonne, Besançon, Bordeaux, Clermont-Ferrand, Corbeil-Essonnes, Créteil Cedex, Epagny Metz-tessy, Grenoble Cedex 9, Le Chesnay Rocquencourt, Lens, Libourne, Lille Cedex, Limoges, Lyon, Mulhouse, Nimes Cedex 9, ORLEANS, PARIS, Perpignan Cedex, Reims Cedex, Rouen, Saint-Brieuc, Toulouse Cedex 9, Tours, Valence, Vandoeuvre Les Nancy, Vannes
- Age
- 18 years and over
- People
- 42
- Run by
- French Innovative Leukemia Organization (F.I.L.O.).
See details and how to join2026-525763-40-00 - Phase 2Taking peopleFaecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
- Where
- Amiens, Angers, Besançon, Clermont-Ferrand, Grenoble, Lille, Limoges, Lyon, Nancy, Nantes, Nice, Paris, Pessac, Poitiers, Rouen, Saint-Etienne, Toulouse
- Age
- 18 years and over
- People
- 150
- Run by
- University Hospital, Clermont-Ferrand
See details and how to joinNCT04935684 - Phase 2Not yet taking people in FranceStudy of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Where
- Argenteuil Cedex, Avignon, Bayonne, Bordeaux, Clermont-Ferrand, Corbeil-Essonnes, Grenoble Cedex 9, Le Chesnay Cedex, Le Mans Cedex 9, Lille Cedex, Lyon, Orleans Cedex 2, Pierre-Bénite, Pontoise, Rouen Cedex, Toulouse Cedex 9, Vandoeuvre Les Nancy Cedex
- Age
- 80 years and over
- People
- 95
- Run by
- The Lymphoma Academic Research Organisation
See details and how to joinNCT07739459 · EU 2025-525080-32-00